Novel drug is potential game changer for acute lymphoblastic leukemia
A new antibody-drug conjugate (ADC) that targets B-cell acute lymphoblastic leukemia (B-ALL) is showing early promise in the fight against childhood leukemia. ALL is a
A new antibody-drug conjugate (ADC) that targets B-cell acute lymphoblastic leukemia (B-ALL) is showing early promise in the fight against childhood leukemia. ALL is a
During the event, children battling cancer participated in Hyundai Hope On Wheels’ signature Handprint Ceremony, in which they dipped their hands in paint and placed
Dr. Brianne Roby, director of the cleft and craniofacial team in the ear, nose and throat (ENT) and facial plastic surgery program on the St.
After graduating college with a degree in chemistry in 2022, Kyla’s career was suddenly put on hold when doctors found an ovarian tumor. But her
Children’s Minnesota attended the 2023 Pediatric Academic Societies Meeting. Learn more!
The pharmacogenomics program at Children’s Minnesota is the only pediatric-focused program in the Upper Midwest and one of only a few pharmacogenomics programs in the
The research found that Black children with Type 1 diabetes (T1D) were at a higher risk to be readmitted for diabetic ketoacidosis (DKA) compared to
The Midwest Fetal Care Center (MWFCC), a collaboration between Children’s Minnesota and Allina Health, is participating in a large multicenter National Institutes of Health (NIH)-funded
Congratulations to Kelly Bergmann, DO, MS, director of research for the department of emergency medicine at Children’s Minnesota, for being awarded Best Overall Abstract in
Reach us 24/7 for patient referrals, consults, admissions and neonatal transport.
Home | Privacy policy & terms of use | Contact us
© 2025 Children’s Minnesota
Children’s Minnesota is registered as a 501(c)(3) non-profit organization. Our tax identification number is 41-1754276.